$ADCT
ADC Therapeutics SA Stock $adct

$adct Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000162828024046050 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$18.46M	$14.49M
YoY Change		27.4%	-81.01%
Cost Of Revenue		$851.0K	$366.0K
YoY Change		132.51%	-30.68%
Gross Profit		$17.61M	$14.13M
YoY Change		24.68%	-81.36%
Gross Profit Margin		95.39%	97.47%
Selling, General & Admin		$20.68M	$23.04M
YoY Change		-10.25%	-36.72%
% of Gross Profit		117.38%	163.06%
Research & Development		$32.50M	$26.93M
YoY Change		20.7%	-35.03%
% of Gross Profit		184.53%	190.61%
Depreciation & Amortization		$336.0K	$796.0K
YoY Change		-57.79%	39.16%
% of Gross Profit		1.91%	5.63%
Operating Expenses		$53.18M	$50.41M
YoY Change		5.5%	-35.49%
Operating Profit		-$35.56M	-$36.28M
YoY Change		-1.97%	1445.76%
Interest Expense		$13.12M	-$11.03M
YoY Change		-218.9%	29.62%
% of Operating Profit
Other Income/Expense, Net		-$8.055M	$244.0K
YoY Change		-3401.23%	100.0%
Pretax Income		-$43.60M	-$47.89M
YoY Change		-8.96%	-6.68%
Income Tax		$100.0K	-$86.00K
% Of Pretax Income
Net Earnings		-$43.97M	-$47.81M
YoY Change		-8.03%	-5.53%
Net Earnings / Revenue		-238.13%	-329.86%
Basic Earnings Per Share		-$0.42	-$0.57
Diluted Earnings Per Share		-$0.42	-$0.58
COMMON SHARES
Basic Shares Outstanding	96.69M shares	96.65M shares	82.26M shares
Diluted Shares Outstanding		104.8M shares	82.26M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$274.3M	$310.4M
YoY Change	-11.64%	-18.5%
Cash & Equivalents	$274.3M	$310.4M
Short-Term Investments
Other Short-Term Assets	$18.63M	$21.28M
YoY Change	-12.46%	16.66%
Inventory	$16.07M	$22.73M
Prepaid Expenses
Receivables	$24.03M	$21.18M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$333.0M	$375.6M
YoY Change	-11.34%	-14.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.721M	$15.53M
YoY Change	-63.17%	57.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$26.99M
YoY Change	-100.0%	-22.19%
Other Assets	$1.165M	$36.42M
YoY Change	-96.8%	5.58%
Total Long-Term Assets	$16.07M	$91.30M
YoY Change	-82.39%	-2.52%
TOTAL ASSETS
Total Short-Term Assets	$333.0M	$375.6M
Total Long-Term Assets	$16.07M	$91.30M
Total Assets	$349.1M	$466.9M
YoY Change	-25.23%	-12.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.37M	$8.977M
YoY Change	60.1%	-22.69%
Accrued Expenses	$53.31M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$15.75M
YoY Change		18.36%
Total Short-Term Liabilities	$67.68M	$78.21M
YoY Change	-13.46%	-10.7%
LONG-TERM LIABILITIES
Long-Term Debt	$436.8M	$413.0M
YoY Change	5.75%	32.57%
Other Long-Term Liabilities	$7.649M	$29.83M
YoY Change	-74.35%	7.16%
Total Long-Term Liabilities	$7.649M	$442.9M
YoY Change	-98.27%	30.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$67.68M	$78.21M
Total Long-Term Liabilities	$7.649M	$442.9M
Total Liabilities	$521.0M	$521.1M
YoY Change	-0.01%	22.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.463B
YoY Change
Common Stock	$8.233M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$222.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	-$171.9M	-$54.18M
YoY Change
Total Liabilities & Shareholders Equity	$349.1M	$466.9M
YoY Change	-25.23%	-12.2%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$43.97M	-$47.81M
YoY Change	-8.03%	-5.53%
Depreciation, Depletion And Amortization	$336.0K	$796.0K
YoY Change	-57.79%	39.16%
Cash From Operating Activities	-$25.04M	-$34.01M
YoY Change	-26.37%	-1649.57%
INVESTING ACTIVITIES
Capital Expenditures	$216.0K	$659.0K
YoY Change	-67.22%	-359.45%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities	-$216.0K	-$659.0K
YoY Change	-67.22%	159.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-879.0K	-2.304M
YoY Change	-61.85%	-197.42%
NET CHANGE
Cash From Operating Activities	-25.04M	-34.01M
Cash From Investing Activities	-216.0K	-659.0K
Cash From Financing Activities	-879.0K	-2.304M
Net Change In Cash	-26.14M	-36.98M
YoY Change	-29.31%	-958.71%
FREE CASH FLOW
Cash From Operating Activities	-$25.04M	-$34.01M
Capital Expenditures	$216.0K	$659.0K
Free Cash Flow	-$25.26M	-$34.67M
YoY Change	-27.15%	-1515.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32271000	usd
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001771910
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	City Area Code CityAreaCode	21 653
	dei	Local Phone Number LocalPhoneNumber	02 00
	dei	Security12g Title Security12gTitle	Common Shares, par value CHF 0.08 per share
	dei	Trading Symbol TradingSymbol	ADCT
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96689617	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	274272000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	278598000	usd
CY2024Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	24030000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	25182000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	16072000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	16177000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18631000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1282431000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1180545000	usd
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	222000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	541000	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2765873	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	6748809	shares
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	203000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-93000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1462591000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1165000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52101000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	67679000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	67670000	usd
CY2024Q3	adc	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	322625000	usd
CY2023Q4	adc	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	303572000	usd
CY2024Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	114189000	usd
CY2023Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	112730000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7312000	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	99453858	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89041946	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96687985	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82293137	shares
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1335472000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-171946000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-148249000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	349079000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	354782000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18016000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14267000	usd
CY2024Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	448000	usd
CY2023Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	226000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1033000	usd
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Registrant Name EntityRegistrantName	ADC Therapeutics SA
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	V8
	dei	Entity Address Country EntityAddressCountry	CH
	dei	Country Region CountryRegion	41
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16334000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	333005000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	336291000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7649000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8879000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	521025000	usd
CY2023Q3	us-gaap	Revenues Revenues	14493000	usd
	us-gaap	Revenues Revenues	53927000	usd
	us-gaap	Revenues Revenues	52768000	usd
CY2024Q3	adc	Cost Of Revenue Net CostOfRevenueNet	851000	usd
CY2023Q3	adc	Cost Of Revenue Net CostOfRevenueNet	208000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10002000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	50642000	usd
	adc	Cost Of Revenue Net CostOfRevenueNet	4578000	usd
	adc	Cost Of Revenue Net CostOfRevenueNet	1313000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32502000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27080000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	82532000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	96797000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10673000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13730000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	32764000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	43537000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9624000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37129000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	152145000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	178776000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-35564000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-36149000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-98218000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3438000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2703000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	9639000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7250000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	13117000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	12816000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10180000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	8233000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52894000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52417000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10511000	usd
CY2024Q3	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1647000	usd
CY2024Q3	us-gaap	Assets Assets	349079000	usd
CY2023Q4	us-gaap	Assets Assets	354782000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	14372000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15569000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8883000	usd
	us-gaap	Interest Expense InterestExpense	38292000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104824877	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104824877	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82256847	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82256847	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94394355	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94394355	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-46726000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-155022000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	44000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	39000	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	125000	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	118000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	585000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-293000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	524000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	18000	usd
CY2024Q3	adc	Other Comprehensive Income Loss Before Oci Equity Method Investment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeOCIEquityMethodInvestmentNetOfTaxPortionAttributableToParent	541000	usd
	adc	Other Comprehensive Income Loss Before Oci Equity Method Investment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeOCIEquityMethodInvestmentNetOfTaxPortionAttributableToParent	399000	usd
	adc	Other Comprehensive Income Loss Before Oci Equity Method Investment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeOCIEquityMethodInvestmentNetOfTaxPortionAttributableToParent	-100000	usd
CY2024Q3	us-gaap	Oci Equity Method Investment After Tax Parent OciEquityMethodInvestmentAfterTaxParent	0	usd
CY2023Q3	us-gaap	Oci Equity Method Investment After Tax Parent OciEquityMethodInvestmentAfterTaxParent	76000	usd
	us-gaap	Oci Equity Method Investment After Tax Parent OciEquityMethodInvestmentAfterTaxParent	-103000	usd
	us-gaap	Oci Equity Method Investment After Tax Parent OciEquityMethodInvestmentAfterTaxParent	-624000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	541000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-256000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-127119000	usd
CY2023Q3	adc	Other Comprehensive Income Loss Before Oci Equity Method Investment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeOCIEquityMethodInvestmentNetOfTaxPortionAttributableToParent	-332000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	296000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-724000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43428000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46982000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-43969000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	79451000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	dei	Entity File Number EntityFileNumber	001-39071
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Biopôle
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Route de la Corniche 3B
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	1066
	dei	Entity Address City Or Town EntityAddressCityOrTown	Epalinges
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5721000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5622000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9188000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	711000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53307000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	503031000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	351000	usd
CY2024Q3	us-gaap	Revenues Revenues	18464000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	54028000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-126008000	usd
	us-gaap	Interest Expense InterestExpense	33416000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1624000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	860000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1783000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3374000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8055000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9253000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26870000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-29540000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-43619000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-45402000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-125088000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-155548000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	90000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-85000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	487000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4065000	usd
CY2024Q3	adc	Income Loss From Continuing Operations Before Equity Method Investments IncomeLossFromContinuingOperationsBeforeEquityMethodInvestments	-43709000	usd
CY2023Q3	adc	Income Loss From Continuing Operations Before Equity Method Investments IncomeLossFromContinuingOperationsBeforeEquityMethodInvestments	-45317000	usd
	adc	Income Loss From Continuing Operations Before Equity Method Investments IncomeLossFromContinuingOperationsBeforeEquityMethodInvestments	-125575000	usd
	adc	Income Loss From Continuing Operations Before Equity Method Investments IncomeLossFromContinuingOperationsBeforeEquityMethodInvestments	-151483000	usd
CY2024Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-260000	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1409000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1544000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3539000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-43969000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-46726000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-127119000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-155022000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.90
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81516563	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81516563	shares
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-126823000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-155746000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-131670000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-43969000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	44000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	585000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	541000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43428000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	111000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	235000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2806000	usd
CY2024Q3	adc	Stockholders Equity Excluding Oci Period Increase Decrease StockholdersEquityExcludingOCIPeriodIncreaseDecrease	3152000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-171946000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-148249000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-127119000	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	125000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	524000	usd
	adc	Other Comprehensive Income Loss Before Oci Equity Method Investment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeOCIEquityMethodInvestmentNetOfTaxPortionAttributableToParent	399000	usd
	us-gaap	Oci Equity Method Investment After Tax Parent OciEquityMethodInvestmentAfterTaxParent	-103000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	296000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-126823000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	185000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	558000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	60506000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	36925000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4952000	usd
	adc	Stockholders Equity Excluding Oci Period Increase Decrease StockholdersEquityExcludingOCIPeriodIncreaseDecrease	103126000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-171946000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-19696000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-46726000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	39000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-293000	usd
CY2023Q3	adc	Other Comprehensive Income Loss Before Oci Equity Method Investment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeOCIEquityMethodInvestmentNetOfTaxPortionAttributableToParent	-332000	usd
CY2023Q3	us-gaap	Oci Equity Method Investment After Tax Parent OciEquityMethodInvestmentAfterTaxParent	76000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-256000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46982000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	349000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2083000	usd
CY2023Q3	adc	Stockholders Equity Excluding Oci Period Increase Decrease StockholdersEquityExcludingOCIPeriodIncreaseDecrease	2432000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-64246000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-155022000	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	118000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	18000	usd
	adc	Other Comprehensive Income Loss Before Oci Equity Method Investment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeOCIEquityMethodInvestmentNetOfTaxPortionAttributableToParent	-100000	usd
	us-gaap	Oci Equity Method Investment After Tax Parent OciEquityMethodInvestmentAfterTaxParent	-624000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-724000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-155746000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	774000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11275000	usd
	adc	Stockholders Equity Excluding Oci Period Increase Decrease StockholdersEquityExcludingOCIPeriodIncreaseDecrease	12049000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-64246000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-127119000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-155022000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-5750000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4952000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	11275000	usd
	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	20964000	usd
	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	12051000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	1459000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	2322000	usd
	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	-732000	usd
	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	4851000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1036000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	780000	usd
	us-gaap	Depreciation Depreciation	993000	usd
	us-gaap	Depreciation Depreciation	852000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1490000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1568000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1544000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3539000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-292000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-776000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	77000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	212000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1058000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-51787000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	930000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5879000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2055000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-6244000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	457000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-200000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1217000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3398000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-165000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-16107000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1499000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1249000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-936000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	5871000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-101983000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-87053000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	777000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2889000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-777000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2889000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	60506000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	36925000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	adc	Proceeds From Royalties Received Net Of Transaction Costs ProceedsFromRoyaltiesReceivedNetOfTransactionCosts	0	usd
	adc	Proceeds From Royalties Received Net Of Transaction Costs ProceedsFromRoyaltiesReceivedNetOfTransactionCosts	73102000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	558000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	774000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	185000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	98174000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	73876000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4586000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-16066000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	260000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	278598000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	326441000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	274272000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310407000	usd
	us-gaap	Interest Paid Net InterestPaidNet	11942000	usd
	us-gaap	Interest Paid Net InterestPaidNet	11432000	usd
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	11074000	usd
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	7869000	usd
	adc	Noncash Payment For Royalty Financing Transaction NoncashPaymentForRoyaltyFinancingTransaction	-3927000	usd
	adc	Noncash Payment For Royalty Financing Transaction NoncashPaymentForRoyaltyFinancingTransaction	-7611000	usd
	adc	Transaction Costs Recorded In Accounts Payable And Other Current Liabilities TransactionCostsRecordedInAccountsPayableAndOtherCurrentLiabilities	38000	usd
	adc	Transaction Costs Recorded In Accounts Payable And Other Current Liabilities TransactionCostsRecordedInAccountsPayableAndOtherCurrentLiabilities	0	usd
	adc	Number Of Subsidiaries NumberOfSubsidiaries	3	subsidiary
	adc	Number Of Subsidiaries NumberOfSubsidiaries	3	subsidiary
	adc	Number Of Business Segments NumberOfBusinessSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Use of Estimates</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the unaudited condensed consolidated financial statements and accompanying notes. Management bases its estimates on </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></div>
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	274300000	usd
CY2024Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	4000	usd
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	4000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	296000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	296000	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	15994000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	16095000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	78000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	82000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	16072000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	16177000	usd
CY2024Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1036000	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	780000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10954000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9897000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5233000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4275000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5721000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5622000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	336000	usd
	us-gaap	Depreciation Depreciation	993000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	316000	usd
	us-gaap	Depreciation Depreciation	852000	usd
	adc	Number Of Product Candidates Developed And Commercialized In Joint Venture NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture	3	subsidiary
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-43600000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-125100000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-100000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4100000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-45400000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-155500000	usd
CY2024Q3	adc	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	20771000	usd
CY2023Q4	adc	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	24902000	usd
CY2024Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	11127000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	12693000	usd
CY2024Q3	adc	Accrued Gross To Net Sales Adjustment Current AccruedGrossToNetSalesAdjustmentCurrent	8175000	usd
CY2023Q4	adc	Accrued Gross To Net Sales Adjustment Current AccruedGrossToNetSalesAdjustmentCurrent	1543000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1479000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1467000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11755000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11496000	usd
CY2024Q3	adc	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	53307000	usd
CY2023Q4	adc	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	52101000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	733568	shares
CY2024Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	114200000	usd
CY2023Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	112700000	usd
CY2021Q3	adc	Royalty Purchase Agreement RoyaltyPurchaseAgreement	325000000	usd
CY2021Q3	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	225000000	usd
CY2023	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	75000000	usd
CY2022Q4	adc	Deferred Royalty Obligation DeferredRoyaltyObligation	222277000	usd
CY2023	adc	Increase Decrease To Royalty Obligation Additional Proceeds From Sale Of Future Royalties IncreaseDecreaseToRoyaltyObligationAdditionalProceedsFromSaleOfFutureRoyalties	75000000	usd
CY2023	adc	Increase Decrease To Royalty Obligation Transaction Costs IncreaseDecreaseToRoyaltyObligationTransactionCosts	1898000	usd
CY2023	adc	Increase Decrease To Royalty Obligation Royalty Payments IncreaseDecreaseToRoyaltyObligationRoyaltyPayments	-8709000	usd
CY2023	adc	Increase Decrease To Royalty Obligation Interest Expense IncreaseDecreaseToRoyaltyObligationInterestExpense	27915000	usd
CY2023	adc	Increase Decrease To Royalty Obligation Cumulative Catch Up Adjustment Other Net IncreaseDecreaseToRoyaltyObligationCumulativeCatchUpAdjustmentOtherNet	-4972000	usd
CY2023Q4	adc	Deferred Royalty Obligation DeferredRoyaltyObligation	309613000	usd
	adc	Increase Decrease To Royalty Obligation Royalty Payments IncreaseDecreaseToRoyaltyObligationRoyaltyPayments	-3927000	usd
	adc	Increase Decrease To Royalty Obligation Interest Expense IncreaseDecreaseToRoyaltyObligationInterestExpense	24891000	usd
	adc	Increase Decrease To Royalty Obligation Cumulative Catch Up Adjustment Other Net IncreaseDecreaseToRoyaltyObligationCumulativeCatchUpAdjustmentOtherNet	-732000	usd
CY2024Q3	adc	Deferred Royalty Obligation DeferredRoyaltyObligation	329845000	usd
	adc	Capital And Interest Guarantee Defined Benefit Plan CapitalAndInterestGuaranteeDefinedBenefitPlan	1
CY2024Q3	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	185000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	143000	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	532000	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	590000	usd
CY2024Q3	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	40000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	74000	usd
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	115000	usd
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	223000	usd
CY2024Q3	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	63000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	82000	usd
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	181000	usd
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	247000	usd
CY2024Q3	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-44000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-39000	usd
	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-125000	usd
	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-118000	usd
CY2024Q3	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	118000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	96000	usd
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	341000	usd
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	448000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.08
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52894000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1033000	usd
CY2024Q3	us-gaap	Revenues Revenues	18464000	usd
CY2023Q3	us-gaap	Revenues Revenues	14493000	usd
	us-gaap	Revenues Revenues	53927000	usd
	us-gaap	Revenues Revenues	52768000	usd
CY2024Q3	us-gaap	Revenues Revenues	18464000	usd
CY2023Q3	us-gaap	Revenues Revenues	14493000	usd
	us-gaap	Revenues Revenues	53927000	usd
	us-gaap	Revenues Revenues	52768000	usd
CY2024Q2	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	14508000	usd
CY2024Q3	adc	Gross To Net Sales Adjustment Provision GrossToNetSalesAdjustmentProvision	6487000	usd
CY2024Q3	adc	Gross To Net Sales Adjustment Prior Period Adjustment GrossToNetSalesAdjustmentPriorPeriodAdjustment	-378000	usd
CY2024Q3	adc	Gross To Net Sales Adjustment Credits And Payments GrossToNetSalesAdjustmentCreditsAndPayments	-4224000	usd
CY2024Q3	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	16393000	usd
CY2023Q4	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	11337000	usd
	adc	Gross To Net Sales Adjustment Provision GrossToNetSalesAdjustmentProvision	18608000	usd
	adc	Gross To Net Sales Adjustment Prior Period Adjustment GrossToNetSalesAdjustmentPriorPeriodAdjustment	-1442000	usd
	adc	Gross To Net Sales Adjustment Credits And Payments GrossToNetSalesAdjustmentCreditsAndPayments	-12110000	usd
CY2024Q3	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	16393000	usd
CY2023Q2	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	5734000	usd
CY2023Q3	adc	Gross To Net Sales Adjustment Provision GrossToNetSalesAdjustmentProvision	6547000	usd
CY2023Q3	adc	Gross To Net Sales Adjustment Prior Period Adjustment GrossToNetSalesAdjustmentPriorPeriodAdjustment	-8000	usd
CY2023Q3	adc	Gross To Net Sales Adjustment Credits And Payments GrossToNetSalesAdjustmentCreditsAndPayments	-3482000	usd
CY2023Q3	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	8791000	usd
CY2022Q4	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	3746000	usd
	adc	Gross To Net Sales Adjustment Provision GrossToNetSalesAdjustmentProvision	17946000	usd
	adc	Gross To Net Sales Adjustment Prior Period Adjustment GrossToNetSalesAdjustmentPriorPeriodAdjustment	-885000	usd
	adc	Gross To Net Sales Adjustment Credits And Payments GrossToNetSalesAdjustmentCreditsAndPayments	-12016000	usd
CY2023Q3	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	8791000	usd
CY2024Q3	adc	Trade And Other Current Receivables Sales Adjustment TradeAndOtherCurrentReceivablesSalesAdjustment	2263000	usd
CY2023Q4	adc	Trade And Other Current Receivables Sales Adjustment TradeAndOtherCurrentReceivablesSalesAdjustment	2403000	usd
CY2024Q3	adc	Current And Accrued Expenses And Other Current Liabilities Sales Adjustment CurrentAndAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment	14130000	usd
CY2023Q4	adc	Current And Accrued Expenses And Other Current Liabilities Sales Adjustment CurrentAndAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment	8934000	usd
CY2024Q3	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	16393000	usd
CY2023Q4	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	11337000	usd
CY2024Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	3400000	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	9600000	usd
CY2023Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	2700000	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	7300000	usd
CY2024Q3	adc	Deferred Royalty Obligation Interest Expense DeferredRoyaltyObligationInterestExpense	8532000	usd
CY2023Q3	adc	Deferred Royalty Obligation Interest Expense DeferredRoyaltyObligationInterestExpense	8087000	usd
	adc	Deferred Royalty Obligation Interest Expense DeferredRoyaltyObligationInterestExpense	24891000	usd
	adc	Deferred Royalty Obligation Interest Expense DeferredRoyaltyObligationInterestExpense	19662000	usd
CY2024Q3	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
CY2023Q3	us-gaap	Interest Expense Other InterestExpenseOther	1000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
	us-gaap	Interest Expense Other InterestExpenseOther	6000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	13117000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	12816000	usd
	us-gaap	Interest Expense InterestExpense	38292000	usd
	us-gaap	Interest Expense InterestExpense	33416000	usd
CY2024Q3	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	-206000	usd
CY2023Q3	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	-437000	usd
	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	-732000	usd
	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	4851000	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	21000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	39000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-75000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2000	usd
CY2024Q3	adc	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-267000	usd
CY2023Q3	adc	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-244000	usd
	adc	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-834000	usd
	adc	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-699000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1624000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	860000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1783000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3374000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.00
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10744406	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M20D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1055800	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	514845	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	31.17
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	957102	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.25
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	87822	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.94
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10240437	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	5213316	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10240437	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	13.55
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M28D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.73
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	5027121	shares
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	9000000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-43969000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-46726000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-127119000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-155022000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104824877	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104824877	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82256847	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82256847	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94394355	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94394355	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81516563	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81516563	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.90
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20852503	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16704626	shares
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-046050-index-headers.html	Edgar Link	pending
0001628280-24-046050-index.html	Edgar Link	pending
0001628280-24-046050.txt	Edgar Link	pending
0001628280-24-046050-xbrl.zip	Edgar Link	pending
adc-20240930.htm	Edgar Link	pending
adc-20240930.xsd	Edgar Link	pending
adc-20240930_g1.jpg	Edgar Link	pending
ex311-ceocertification302q.htm	Edgar Link	pending
ex312-cfocertification302q.htm	Edgar Link	pending
ex321-ceocertification906q.htm	Edgar Link	pending
ex322-cfocertification906q.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
adc-20240930_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
adc-20240930_cal.xml	Edgar Link	unprocessable
adc-20240930_lab.xml	Edgar Link	unprocessable
adc-20240930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
adc-20240930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADCT
ADC Therapeutics SA Stock $adct

2024 Q4 Form 10-Q Financial Statement

#000162828024046050 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADCT ADC Therapeutics SA Stock $adct

2024 Q4 Form 10-Q Financial Statement

#000162828024046050 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADCT
ADC Therapeutics SA Stock $adct